Deucravacitinib (Sotyktu), an oral medication, allosterically inhibits tyrosine kinase 2, an enzyme that mediates signaling for key cytokines such as IL-23 and type I interferons, which are implicated in inflammatory diseases like psoriasis.10 The gene discussed is TYK2; the disease is psoriasis.